The psychoactive agent N-methyl-l-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) was identified in urine samples from ten people suspected of petty drug offences. MBDB is a selective serotonin-releasing agent and the 0~-ethyl homologue of 3,4-methylenedioxymethamphetamine (MDMA). The presence of MBDB was confirmed by comparing the mass spectra of the urine samples with the mass spectrum of authentic reference substance. Quantitation of MBDB, MDMA, 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxyethylamphetamine (MDE) was performed with gas chromatography-mass spectrometry with trifluoroacetic anhydride as the derivatizing agent. Concentrations of MBDB in urine specimens ranged from 0.1-24 pg/mL. The demethylated metabolite of MBDB, 3,4-(methylenedioxyphenyl)-2-butanamine (BDB), was also detected in the urine specimens. In seven of the ten samples, MBDB and BDB were the only ecstasy analogues found, but the samples were positive for several other drugs. This appears to be the first report on MBDB as an abused drug in Sweden.
Introduction
N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) is the c~-ethyl homologue of 3,4-methylenedioxymethamphetamine (MDMA). MBDB is a selective serotoninreleasing agent that has few or no dopaminergic effects because of the ethyl group in the co-position (1) . Both (~-ethylation and N-alkylation of hallucinogenic amphetamines have been shown to attenuate hallucinogenic properties (2) . Because of the lack of both dopaminergic and hallucinogenic activity, MBDB has been proposed as the prototype of a new pharmacological class, the entactogens, which is a name derived from Latin and Greek roots that means "to produce a touching within" (3) . Applications exist in psychotherapy as the effects involve enhanced closeness and communication in combination with reduced emotional integrity, which could facilitate therapy. 3,4-Methylenedioxyamphetamine (MDA), MDMA, and 3,4-methylenedioxyethylamphetamine (MDE) influence emotions in the same manner, but also possess hallucinogenic (MDA) or dopaminergic (MDA, MDMA, MDE) activity (3) .
The ecstasy analogues appear to be abused interchangeably or in combination, especially because tablets often contain more than one substance (4) . In seven of ten cases reported here, however, MBDB and its demethylated metabolite, 3,4-(methylenedioxyphenyl)-2-butanamine (BDB), were the only ecstasy analogues present.
Case History
During routine analysis of a urine sample from an individual suspected of a petty drug offense, two unidentified peaks appeared in the gas chromatographic-mass spectrometric (GC-MS) chromatogram for the confirmation of amphetamines. One peak eluted between MDA-d5 and MDMA-d5, and the second eluted slightly after MDE-d5 when derivatized with trifluoroacetic anhydride (TFAA). The urine sample was positive when screened with both Syva EMIT (San Jose, CA) and Abbott TDx (Abbott GmbH, Wiesbaden, Germany) reagents for amphetamines, but was negative for amphetamine, methamphetamine, phenmetrazine, ephedrine, norephedrine, MDA, MDMA, and MDE in the confirmation analysis. Further analysis of underivatized sample with GC-MS showed the presence of substances with spectra that matched those of BDB and MBDB according to spectra library from Pfleger et al. (5) . After this finding, the method for amphetamines was modified to monitor ions from MBDB. No other positive samples occurred in the approximately 4000 samples, which were obtained over the next few months, that were positive for amphetamines. Recently, however, during a two-month period, nine additional samples were confirmed positive for the presence of MBDB.
Experimental
MBDB-HC1 was a gift from Landeskriminalamt (SchleswigHolstein, Germany).
MDA, MDMA, and MDE and the deuterated homologues were purchased from Radian Corp. (Austin, TX). Solvents and sodium hydroxide were of analytical grade and purchased from Merck (Darmstadt, Germany). TFAA was purchased from Aldrich (Steinheim, Germany). Standard solutions used for controls and calibration were prepared separately by combining MDA, MDMA, and MDE standards in methanol. MBDB control and calibration solutions were prepared separately from the other analytes. The internal standard was prepared by combining MDA-ds, MDMA-ds, and MDE-d5 in methanol.
Samples for calibration curves and controls were made by adding standard solutions to drug-free urine, and aliquots were frozen until analysis. Calibrators for MDA, MDMA, and MDE contained 0.2, 1.0, 2.0, 5.0, and 10.0 pg/mL urine, and MBDB calibrators contained 0.05, 0.1, 0.2, 1.0, 2.0, and 5.0 pg/mL urine.
Extraction
The drugs were extracted from urine (0.2 mL) with 2 mL isooctane after adding 0.2 mL 2M sodium hydroxide and 200 ng internal standard. The organic phase was transferred to a new tube and evaporated under a stream of nitrogen. After derivatization with 100 pL of TFAA at 60~ for 15 rain, the samples were evaporated and reconstituted in 50 pL isooctane. Samples outside the calibration curve were diluted and re-extracted. Also, 0.5-mL aliquots were extracted without derivatization for spectral analysis.
Instrumentation
Screening analysis was done with Syva EMIT d.a.u, polyclonal amphetamine reagent on a Hitachi 717 (Boehringer, Mannheim, Indianapolis, IN) analyzer and with the Abbott Amphetamine/Methamphetamine reagent and an Abbott TDx system. GC-MS quantitation and electron impact (EI) spectra were performed on a Hewlett Packard (Palo Alto, CA) 5890 GC interfaced to a 5972A mass selective detector. A 7673A autosampler was used for the injections. The column was a 30-m HP-5 MS with 0.25-mm internal diameter and 0.25-pro film thickness. Helium was used as the carrier gas at a constant flow of 0.9 mL/min. A 1.0-pL aliquot was injected in splitless mode (1 min splitless time) using a silanized 250-pL liner with a silanized glass-wool plug. Injector and interface temperatures were 210 and 280~ respectively. The oven temperature was held at 85~ for 1 min and then increased at 30~ to 280~ The scan was performed from m/z 40-550. For spectra comparison the HP Chemstation Library Search program was used with the default settings. The ions monitored for quantitation are listed in Table I . MBDB was quantitated using MDE-ds as internal standard.
Results and Discussion
Linear calibration curves were established between 0.05-5 pg/mL for MBDB and between 0.2-10 pg/mL for MDA, MDMA, and MDE. The threshold concentration for detection of MBDB was set at 0.05 pg/mL and at 0.2 mg/mL for the others. When determining the between-day precision (n = 10) the coefficients of variation (CV) for the analytes at 0.2 pg/mL were 12, 14, 3.8, and 6.4% for MDA, MDMA, MDE, and MBDB, respectively. At 2.0 pg/mL, CVs were 11, 6.5, 3.6, and 7.6% for MDA, MDMA, MDE, and MBDB, respectively. SIM chromatograms from a representative sample (#5) and a standard sample are shown in Figure 1 . Good chromatographic separation was achieved for the analytes as TFA derivatives. When performing a scan from m/z 40-550, the unidentified peaks, 2 and 5, in Figure 1 showed spectra similar to those of MDA and MDMA, respectively, although mass frag-ments were 14 ainu higher, indicating an additional methyl group (Figure 2) . Ions m/z 135 (all), m/z 140 (Figure 2A) , m/z 154 ( Figures 2B and 2D) , and m/z 168 ( Figures 2C, 2E , and 2F) were produced by o~-cleavage with the charge on the ring side (m/z 135) or on the amide side. For the secondary amides (Figures 2A and 2D) , the location of charge was in favor of the ring side, whereas the tertiary amides favored the amide side. Base peaks for all analytes were produced by m-cleavage. The mass fragment m/z 176 for BDB and MBDB resulted from cleavage adjacent to the nitrogen, and corresponds to m/z 162 fragment for MDA, MDMA, and MDE. Spectra of peak 5 for all the samples were compared with that of the MBDB reference and showed match probability factors of 98% or more. In combination with retention time, this was considered evidence of identification. In Figure 3 , a chromatogram from sample 5, underivatized, is shown in addition to spectra from the peaks corresponding to underivatized BDB and MBDB. Good visual correlation between spectra of peak 1 from underivatized samples and spectra for BDB from Pfleger et al. (5) was found. This, and additional mass spectral information from TFA-derivatives, were considered evidence of identity, even though no reference substance for BDB was available. Therefore, BDB was not quan- titated. Tablets containing both MBDB and BDB have been encountered, and whether the BDB found in the samples was exclusively a metabolic product or also originally present in the ingested tablets is unclear. Analytical findings of ecstasy analogues from the samples are presented in Table II . All the samples were positive for at least one other drug, usually marijuana (six cases). The samples containing MBDB came from three major cities in Sweden during a period of two months (excluding the initial case). The age of the arrestees ranged from 19-28 years with a median age of 20, and three of them were attending rave parties (Subjects 8-10) when arrested.
Conclusion
The present work shows that, on a small scale, MBDB is abused in Sweden, particularly by young people. In seven of ten samples, MBDB and BDB were the only ecstasy analogues identified, suggesting that a choice was made between MBDB and MDA, MDMA, or MDE. As MBDB is not yet listed as a narcotic in Sweden, and those who use MBDB are not breaking the law, this may favor use of MBDB instead of the other ecstasy analogues that are listed. In these cases, however, this seems unlikely because all the urine samples were positive for other listed drugs.
